Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX).
- Disclosed ownership: 9.9%.
- Date of event: 09 Mar 2026.
Commodore Capital LP - 09 Mar 2026 SCHEDULE 13G Report for AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- ANTX
- Shares outstanding
- 37,347,828 shares
- Disclosed Ownership
- 3,697,435 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 16 Mar 2026, 16:21:14 UTC
- Date of event
- 09 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 9.9% ownership in AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX) on 09 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 16 Mar 2026, 16:21.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 3,697,435 | 0 | 3,697,435 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 9.9% | 3,697,435 | 0 | 3,697,435 | Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 9.9% | 3,697,435 | 0 | 3,697,435 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 9.9% | 3,697,435 | 0 | 3,697,435 | Michael Kramarz | Authorized Signatory |